Articles

Mastering MS

New drug could be 50 to 100 times more potent than existing options
Written byIlene Schneider
| 3 min read

NEW YORK—Multiple sclerosis (MS) is the most common cause of non-traumatic disability in young adults. Nearly one million people are living with MS in the United States, with about 300,000 people receiving treatment. Roughly 85 percent are initially diagnosed with the relapsing remitting form of MS (RRMS), which is the most common form of MS and is characterized by episodes of new or worsening signs or symptoms, followed by periods of recovery.

“With a current market of $18 to $20 billion and a projected market of $25 billion, MS is a large and growing problem,” said Michael Weiss, CEO and president of TG Therapeutics, which was founded in 2012 to create the best possible treatment options for patients with B cell diseases, focusing on autoimmune and oncology applications. The company began by licensing a potential drug from LFB Biotech, a subsidiary of Ministry of Health, France.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
Blue microscopic illustration of spherical cells with textured surfaces against a dark background.
Explore how longitudinal single-cell profiling of whole blood can reveal immune signatures associated with CAR T cell therapy-related neurotoxicity.